Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone

Marion Depenbusch, Sigrid von Eckardstein, Manuela Simoni and Eberhard Nieschlag
Institute of Reproductive Medicine of the University, Domagkstr. 11, D-48149 Münster, Germany

Abstract

Objective: It is generally accepted that both gonadotropins LH and FSH are necessary for initiation and maintenance of spermatogenesis. We investigated the relative importance of FSH for the maintenance of spermatogenesis in hypogonadotropic men.

Subjects and methods: 13 patients with gonadotropin deficiency due to idiopathic hypogonadotropic hypogonadism (IHH), Kallmann syndrome or pituitary insufficiency were analyzed retrospectively. They had been treated with gonadotropin-releasing hormone (GnRH) ($n=1$) or human chorionic gonadotropin/human menopausal gonadotropin (hCG/hMG) ($n=12$) for induction of spermatogenesis. After successful induction of spermatogenesis they were treated with hCG alone for maintenance of secondary sex characteristics and in order to check whether sperm production could be maintained by hCG alone. Serum LH, FSH and testosterone levels, semen parameters and testicular volume were determined every three to six months.

Results: After spermatogenesis had been successfully induced by treatment with GnRH or hCG/hMG, hCG treatment alone continued for 3–24 months. After 12 months under hCG alone, sperm counts decreased gradually but remained present in all patients except one who became azoospermic. Testicular volume decreased only slightly and reached 87% of the volume achieved with hCG/hMG. During treatment with hCG alone, FSH and LH levels were suppressed to below the detection limit of the assay.

Conclusion: Once spermatogenesis is induced in patients with secondary hypogonadism by GnRH or hCG/hMG treatment, it can be maintained in most of the patients qualitatively by hCG alone, in the absence of FSH, for extended periods. However, the decreasing sperm counts indicate that FSH is essential for maintenance of quantitatively normal spermatogenesis.

European Journal of Endocrinology 147 617–624
the patients be maintained qualitatively with hCG alone for extended periods.

Subjects and methods

Subjects
In an open uncontrolled retrospective trial we studied 13 of all patients with secondary hypogonadism who were treated with GnRH or hCG/hMG for induction of spermatogenesis. The selection criterion for these 13 patients was, that after spermatogenesis had been successfully induced, they were treated with hCG instead of testosterone preparations for the maintenance of secondary sex characteristics. Gonadotropin deficiency resulted from IHH \((n = 3)\), Kallmann syndrome \((n = 4)\) or pituitary insufficiency (pre-pubertal: \(n = 2\), post-pubertal: \(n = 4\)). In most cases pituitary insufficiency was due to pituitary tumors (Table 1). Some patients had a history of treated unilateral or bilateral maldescended testes: all patients with IHH, one patient with Kallmann syndrome and one with post-pubertal pituitary insufficiency. Clinical examinations had been performed at intervals of 3 to 6 months. Patients’ ages ranged from 19 to 38 years at the beginning of treatment, all were azoospermic and had serum LH and FSH levels below the normal range.

Treatment
Patients with secondary hypogonadism can be effectively treated with pulsatile GnRH or hCG/hMG in order to induce spermatogenesis (14). In this study one patient received pulsatile GnRH \((5 \mu g/120 \text{ min})\) and 12 patients received hCG/hMG therapy according to common clinical guidelines with \(3 \times 150 \text{ IU hMG} \) subcutaneously per week and individually adapted hCG doses ranging from \(2 \times 500\) to \(2500 \text{ IU} \) per week (1). After successful induction of spermatogenesis testosterone production was maintained with hCG instead of substituting testosterone. Treatment was continued as long as patients preferred hCG over testosterone substitution. For analysis of data we differentiated 4 different phases of treatment.

Phase 1 – testosterone treatment
Patients received either testosterone enanthate (Testoviron-Depot-250, Schering, Berlin, Germany) \(250 \text{ mg/14–28 days intra-muscularly, or transdermal testosterone (Testoderm 15, Ferring, Kiel, Germany) 15 mg/day applied on the scrotum.}

Phase 2 – hCG alone treatment (only in those patients subsequently treated with hCG/hMG)
Patients received \(500–2500 \text{ IU} \) hCG (Choragon 1500, Ferring; Primogonyl, Schering; Pregnesin 5000, Serono, Unterschleißheim, Germany; Predalon 500,
Organon, Oberschleißheim, Germany), twice per week subcutaneously.

**Phase 3 – hCG/hMG treatment** While continuing the same dosage of hCG, each patient simultaneously received 150 IU hMG (Menogon, Ferring; Fertinorm HP 150, Serono; Gonaf 150, Serono), three times weekly subcutaneously. Pulsatile GnRH treatment: the patient received 5 μg GnRH/120 min subcutaneously using a Zyklomat pulse set (Lutrelef, Ferring).

**Phase 4 – hCG alone treatment** Immediately after successful induction of spermatogenesis with GnRH or hCG/hMG or achievement of pregnancy, patients continued to receive individual doses of hCG (500–2500 IU twice weekly) subcutaneously, adjusted to trough serum testosterone levels to be maintained in the normal range.

**Methods**
During the course of treatment, physical and clinical control examinations such as semen analysis, determination of testicular volume and hormone analysis were performed every three to six months. Blood samples were drawn for hormone measurements as well as hematology and clinical chemistry (data not shown).

**Hormone analysis** LH and FSH were analyzed by immunofluorometric assays (Delfia, Wallac, Freiburg, Germany). The lower detection limits were 0.12 IU/l for LH and 0.25 IU/l for FSH. The normal range is 2–10 IU/l for LH and 1–7 IU/l for FSH. Interassay variance of all assays did not exceed 6.5% for LH and 4.5% for FSH. Serum testosterone was determined using a commercial fluoroimmunoassay (Delfia, Wallac). The lower detection limit was 0.5 nmol/l. The normal range for testosterone is above 12 nmol/l. Interassay variance of all assays did not exceed 12.9%.

**Semen analysis** Semen parameters were analyzed according to WHO guidelines (15) and subjected to internal (16) and external (17) quality control.

**Testicular volume** Determination of testicular volume was performed by palpation and sonography using a 7.5 Mhz sector scan until 1999 (Sonoline Versa Pro, Siemens, Erlangen, Germany), thereafter using a high

---

**Figure 1** Individual sperm concentrations and testicular volumes. (A) Individual sperm concentrations in men with IHH (n = 3, open symbols) or Kallmann syndrome (n = 4, solid symbols) under hCG/hMG or hCG alone. (B) Individual testicular volumes in men with IHH (n = 2, open symbols) or Kallmann syndrome (n = 2, solid symbols) under hCG/hMG or hCG alone. (C) Individual sperm concentrations in men with pre-pubertal (n = 2, open symbols) or post-pubertal (n = 4, solid symbols) pituitary insufficiency under hCG/hMG or hCG alone. (D) Individual testicular volumes in men with pre-pubertal (n = 1, open symbols) or post-pubertal (n = 3, solid symbols) pituitary insufficiency under hCG/hMG or hCG alone. T, testosterone.
frequency 7.5 MHz convex scanner (Ultrasound Scanner Type 2002 ADI, B&K Medical, Gentofte, Denmark). The procedure for calculation of testicular volume has been described previously (18, 19).

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism software (version 2.01). Results are given as means±s.d. Differences between groups were tested by Mann–Whitney rank sum test.

**Results**

**Treatment**

Patients had been pretreated with testosterone (phase 1) for a median duration of 20 months with a minimum of 5 months and a maximum of 14 years. Treatment with hCG alone (phase 2) lasted for a median time of 3.5 months with a minimum of 1 month and a maximum of 6 months. Induction of spermatogenesis with pulsatile GnRH or hCG/hMG (phase 3) lasted for a median time of 16 months with a minimum of five months and a maximum of 57 months (individual treatment periods are given in Table 1). As previously reported (14), the testicular volume at the beginning of therapy was a significant predictor (P = 0.017) for the necessary length of hCG/hMG or GnRH treatment until spermatogenesis was induced. At the end of GnRH or hCG/hMG treatment patients had a median sperm concentration of 3.3 millions/ml (mill/ml) with a minimum of 0.1 mill/ml and a maximum of 210 mill/ml. Bitesticular volumes had increased initially from a mean volume of 6.5 ml (minimum: 2.4 ml, maximum: 40 ml) to a mean of 24.0 ml (minimum: 10.2 ml, maximum: 57.2 ml). In four patients not desiring pregnancy, induction of spermatogenesis was terminated after sperm had appeared in the ejaculate. Five of nine patients successfully induced pregnancies. These results are comparable to those published previously on a larger cohort (14).

After GnRH or hCG/hMG treatment, testosterone production was maintained with administration of hCG alone (phase 4). The median treatment duration was 10 months with a minimum of three and a maximum of 25 months (individual treatment periods are given in Table 1). hCG alone maintained spermatogenesis at a lower concentration in all patients, with the exception of one who became azoospermic after four months. This patient only achieved a sperm concentration of 0.1 mill/ml after five months treatment with hCG/hMG. After six months semen parameters of 10 patients were analyzed. The median sperm concentration was 0.5 mill/ml with a minimum of 0.1 mill/ml and a maximum of 94 mill/ml (Fig. 1A and 1C). When considering the maximum response to GnRH or hCG/hMG treatment as 100%, after six months treatment with hCG alone sperm concentration was 31% of the concentration achieved with GnRH or hCG/hMG (Fig. 2). Testicular volume achieved at the end of GnRH or hCG/hMG treatment was also considered to be equal to 100% in each individual. After six months with hCG alone the testicular volume of seven patients was determined and reached 80% of maximum (Fig. 3).

After 12 months with hCG alone, semen parameters and testicular volume of four patients were available for analysis. The median sperm count was 1.55 mill/ml with a minimum of 0.1 mill/ml and a maximum of 74.3 mill/ml (Fig. 1A and 1B). Expressed as a percentage of the maximum response to GnRH or hCG/hMG, the mean sperm concentration was 43% (Fig. 2) and the mean testicular volume was 87% (Fig. 3).
After 15 months with hCG alone semen parameters of four patients and testicular volume of five patients were available for analysis. The median sperm count was 1.25 mill/ml with a minimum of 0.1 mill/ml and a maximum of 8.3 mill/ml (Fig. 1A and 1B). Expressed as a percentage of the maximum response under GnRH or hCG/hMG, the mean sperm concentration was still 25.6% (Fig. 2) and the mean testicular volume was 86% (Fig. 3).

After 24 months with hCG alone, semen parameters and testicular volume of three patients were available for analysis. The median sperm count was 1.7 mill/ml with a minimum of 0.4 mill/ml and a maximum of 3.6 mill/ml (Fig. 1A and 1B). Expressed as a percentage of the maximum response to GnRH or hCG/hMG, the mean sperm concentration was 51.9% (Fig. 2) and the mean testicular volume was 90% (Fig. 3).

Four of the thirteen patients included are currently still under hCG treatment. The others stopped hCG treatment because they had no current wish for a child and wanted to use testosterone treatment to avoid any other method of contraception or because they preferred the application intervals of testosterone injections. One patient wished to achieve paternity and therefore added hMG again.

Comparing the different patient groups there was no obvious difference in the ability to maintain sperm production during treatment with hCG alone. The patients with Kallmann syndrome tended to have lower sperm concentrations and testicular volumes, but this was
not statistically significant. There was also no correlation of the testicular volume or the gonadotropin levels at the beginning of therapy or the treatment duration (neither phase 3 nor phase 4) with the maintained sperm concentrations. However, this might be due to the small patient number in the groups.

**Hormones**

Prior to treatment with GnRH or hCG/hMG all patients had serum FSH and LH levels around the detection limit (FSH: 0.4 ± 0.5 IU/l; LH: 0.2 ± 0.1 IU/l); testosterone levels were in the normal range (19.9 ± 21.6 nmol/l). One patient had detectable serum LH and FSH levels during treatment with hCG alone (phase 2) indicating a partial gonadotropin secretion in this patient. With hCG/hMG treatment testosterone levels remained in the normal range (19.4 ± 10.7 nmol/l). FSH levels rose to the normal range (4.9 ± 2.7 IU/l). LH levels were around the detection limit (0.4 ± 0.6 IU/l) except in one patient who had detectable LH, again probably due to partial gonadotropin secretion. The patient treated with pulsatile GnRH had a serum FSH value of 6.81 IU/l and a serum LH value of 10.7 IU/l and was excluded from the gonadotropin analysis in Fig. 4A and 4B. FSH levels decreased after patients discontinued GnRH or hMG and continued with hCG alone and fell back to below the detection limit (FSH < 0.25 IU/l; Fig. 4B). LH levels were also below the detection limit (LH < 0.12 IU/l; Fig. 4A). Testosterone levels were generally in the normal range (testosterone > 12 nmol/l). If they were below the normal range, this was mostly due to the period of time since the last application of testosterone or hCG. In one patient an insufficient compliance was possible, and in another one the dosage of hCG had to be adjusted (Fig. 4C).

**Discussion**

Male hypogonadotropic hypogonadism (HH), characterized by the absence of endogenous gonadotropin secretion, is a convenient model to assess the effects of LH and FSH on human spermatogenesis. In this retrospective analysis of 13 HH patients we demonstrate that spermatogenesis can, in most of the patients, be maintained qualitatively but not quantitatively for extended periods by treatment with hCG alone in the absence of FSH once it had been induced by GnRH or hCG/hMG therapy, as case reports had shown previously (11).

Studies in rodents, non-human primates and humans have shown that LH/testosterone is essential for spermatogenesis (7, 8, 10, 20–24), while the role of FSH in the maintenance of spermatogenesis remains controversial. In monkeys treated with a GnRH antagonist to suppress pituitary gonadotropin production, the administration of FSH alone was sufficient to maintain spermatogenesis, at least in part (25). Other studies are quoted supporting the hypothesis that spermatogenesis can be completed in the absence of FSH. The FSH β subunit knockout mouse has a qualitatively normal production of sperm in the absence of FSH (26), and mice with a disruption of the FSH receptor also produce qualitatively normal sperm (27). Active immunization against FSH (5) and the FSH receptor in monkeys (28) decreased but did not completely deplete spermatogenesis. However, nonspecific effects of the immunoneutralization procedure are possible (29). It has also previously been described that there are certain differences in spermatogenetic pathways in rodents and primates (29). Recently, two men with a mutation in the FSH β subunit gene and azoospermia have been reported (30, 31). These cases demonstrate the essential role of FSH for the initiation of spermatogenesis but add little information about the role of FSH in the maintenance of spermatogenesis. In an experimental study carried out with normal men, Matsumoto et al. (32) demonstrated that normal levels of FSH are not required for the maintenance of qualitatively normal spermatogenesis but are required for the maintenance of quantitatively normal spermatogenesis. However, it has been suggested that FSH could still be present in this experimental setting as suppression of gonadotropins was achieved with testosterone. Evidence from the non-human primate indicates that even during testosterone application for several months small amounts of biologically active FSH remain present (33). In normal men participating in contraceptive studies it is similarly very difficult to suppress FSH secretion completely (34). This has recently been confirmed using a more sensitive FSH assay (35).

In the testis, LH acts primarily on Leydig cell testosterone production. In the hypogonadal (hpg) mouse, which is completely deprived of gonadotropins due to major deletions in the GnRH gene, it could be shown that application of testosterone is sufficient to induce spermatogenesis and that the threshold of testosterone for maintenance is comparably low (36). In monkeys it has been shown that after surgical hypophysectomy complete but quantitatively reduced spermatogenesis could be maintained with testosterone therapy alone (37). In the human, administration of testosterone after induction of azoospermia with GnRH antagonists resulted in a rebound of sperm production. However, this rebound was only observed after the GnRH antagonist had been withdrawn, leaving the possibility of a short-term increase in LH and/or FSH (38). Earlier case reports on two patients with hypogonadotropic hypogonadism showed that spermatogenesis induced by hCG/hMG could be maintained by hCG alone (11). Long-term treatment with hCG alone in HH patients also effectively induced and maintained spermatogenesis (12). However, the completeness of absence of...
gonadotropins in these cases (sporadic pulses?) remained unclear and the addition of hMG improved sperm function and output in some patients (12). There might be a residual FSH secretion in patients with HH. Notwithstanding, during treatment with hCG alone our patients all had FSH levels below the detection limit of our assay (<0.25 IU/L, Fig. 4B).

Concerning the wide range in sperm concentration observed in this retrospective analysis, the following aspects have to be considered: there are different causes of HH (anatomical lesions, genetic/idiopathic causes). Therefore the age of onset (pre- versus post-pubertal) and the extent of pituitary failure (complete/partial) may lead to differences in the response to treatment. In cases of acquired HH, a more rapid improvement in spermatogenesis in response to gonadotropin therapy is expected compared with the idiopathic/genetic variants, presumably because testicular development had been normal before the onset of disease (39). In our retrospective analysis there is no obvious difference in sperm concentrations achieved by men with different causes of HH, consistent with findings from our larger series of HH patients (14). Another explanation for the wide range of sperm concentration might be pre-existing (i.e. independent of gonadotropins) fertility problems, a history of maldescended testes and the duration of treatment with hCG/hMG.

In summary, FSH and LH/testosterone in combination and alone are able to maintain spermatogenesis to a certain extent. For quantitatively normal spermatogenesis both gonadotropins are required (13). Consistent with these findings, our current study demonstrates that, in patients with HH, once spermatogenesis has been induced by gonadotropin therapy, it can in most of the patients be maintained qualitatively, although quantitatively reduced, with hCG alone at least for some time in the absence of FSH. This has implications for the cost/effectiveness of this treatment since obviously expensive FSH preparations can be eliminated for longer periods once spermatogenesis has been induced.

Acknowledgements

We thank PD Dr Maria Byrne and Susan Nieschlag, MA for language editing of the manuscript.

References


8 Suresh R, Medhamurthy R & Mougdal NR. Comparative studies on the effects of specific immunonutralization of endogenous FSH or LH on testicular germ cell transformations in the adult bonnet monkey (Macaca radiata). American Journal of Reproductive Immunology 1995 34 35–43.

9 Graf KM, Dias JA & Griesdorf MD. Decreased spermatogenesis as the result of an induced autoimmune reaction directed against the gonadotropin receptors in male rats. Journal of Andrology 1997 18 174–185.


19 Behre HM, Kliesch S, Schaedel F & Nieschlag E. Clinical relevance of scrotal and transrectal ultrasonography in andrological

Received 25 March 2002
Accepted 8 July 2002